Kenneth Pennington, MD

Articles by Kenneth Pennington, MD

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

ByKathy D. Miller, MD,Judy Sisk, RN,Rafat Ansari, MD,Gary Gize, MD,Sreenivasa Nattam, MD,Kenneth Pennington, MD,George W. Sledge, Jr, MD

February 1st 2001

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing

Latest Updated Articles

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
February 1st 2001

Kenneth Pennington, MD

Articles by Kenneth Pennington, MD

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

Achieving a “Functional Cure” With Multiple Myeloma Therapy